Specifically, regarding inflammation, trigonelline prevents the transcriptional upregulation of the p50 and p65 subunits of NF-κB [331,332], thereby reducing the expression of TNF-α, IL-1β, IL-6 [65], suggesting that it may potentially be used to prevent the pathogenesis of MS. This evidence concerns the gene NFKB1 and myeloid sarcoma.